Brokerages Set Esperion Therapeutics Inc (ESPR) Price Target at $31.92
Esperion Therapeutics Inc (NASDAQ:ESPR) has earned a consensus recommendation of “Buy” from the fourteen analysts that are currently covering the company, MarketBeat reports. Eight analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $31.92.
Several equities research analysts recently issued reports on the company. Needham & Company LLC set a $25.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a research note on Saturday, March 18th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $30.00 price objective (up from $20.00) on shares of Esperion Therapeutics in a research note on Thursday, February 23rd. Zacks Investment Research raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 2nd. Citigroup Inc. raised Esperion Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $14.00 to $39.00 in a research note on Tuesday, February 28th. Finally, J P Morgan Chase & Co reaffirmed a “hold” rating and set a $50.00 price target (up from $22.00) on shares of Esperion Therapeutics in a research note on Monday, March 20th.
In related news, Director Dov A. Md Goldstein sold 800,000 shares of the business’s stock in a transaction on Wednesday, March 22nd. The stock was sold at an average price of $41.66, for a total value of $33,328,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Gilbert S. Omenn acquired 1,000 shares of the business’s stock in a transaction on Tuesday, March 21st. The stock was acquired at an average price of $42.26 per share, with a total value of $42,260.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $422,600. The disclosure for this purchase can be found here. 32.50% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of ESPR. Quantbot Technologies LP acquired a new position in shares of Esperion Therapeutics during the first quarter valued at about $158,000. C WorldWide Group Holding A S acquired a new position in shares of Esperion Therapeutics during the first quarter valued at about $162,000. Princeton Alpha Management LP acquired a new position in shares of Esperion Therapeutics during the first quarter valued at about $205,000. Bank of Montreal Can increased its position in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares during the last quarter. Finally, American International Group Inc. increased its position in shares of Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 584 shares during the last quarter. Hedge funds and other institutional investors own 81.45% of the company’s stock.
Shares of Esperion Therapeutics (NASDAQ ESPR) opened at 33.39 on Monday. Esperion Therapeutics has a one year low of $9.40 and a one year high of $48.21. The stock’s market cap is $754.28 million. The company has a 50 day moving average of $35.00 and a 200-day moving average of $26.03.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Monday, May 1st. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.44) by $0.36. During the same period in the previous year, the firm earned ($0.65) earnings per share. On average, analysts anticipate that Esperion Therapeutics will post ($6.69) earnings per share for the current year.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Stock Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related stocks with our FREE daily email newsletter.